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Abstract 
 
A 66-year-old woman presented with new onset generalised 
tonic-clonic  seizures  following  her  first  dose  of 
chemotherapy  comprising  Rituximab,  Cyclophosphamide, 
Hydroxydaunorubicin, Oncovin and Prednisolone (R-CHOP) 
10 days earlier for non-Hodgkin’s lymphoma. On admission, 
computed tomography (CT) scan of the cranium showed no 
abnormality. The CT was repeated within 48 hours as the 
patient developed status epilepticus and papilledema; the 
repeat scan showed characteristics of posterior reversible 
encephalopathy syndrome (PRES). Association of rituximab 
with  this  condition  was  suspected  as  there  was  no 
recurrence of PRES after receiving two more cycles of CHOP 
without  rituximab.  Contrary  to  previously  published  case 
reports, this patient had a delayed clinical presentation.   
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Background 
PRES was first described by Hinchey et al. in 1996
1 and the 
pathophysiology  of  the  syndrome  remains  unclear.  It 
presents  with  headaches,  seizures,  loss  of  vision,  and 
altered  mental  status
1,2  with  radiologic  findings  of  focal 
reversible vasogenic oedema. The syndrome is commonly 
found  to  be  associated  with  acute  hypertension,  pre-
eclampsia or eclampsia, renal disease, sepsis, and exposure 
to immunosuppressive agents.
 3 
 
Three theories for a possible underlying mechanism have 
been  suggested:  hypertension  causes  a  breakdown  in 
cerebral auto-regulation which leads to hyperperfusion and 
protein  and  fluid  extravasation  producing  vasogenic 
oedema
4;  vasospasm  leads  to  ischemia
5;  endothelial 
dysfunction  develops  in  patients  with  pre-eclampsia, 
eclampsia and septis.
6 
 
If  undetected,  PRES  may  lead  to  permanent  neurologic 
damage or death.
2 Secondary complications such as status 
epilepticus  (SE),  intracranial  haemorrhage,  and  ischemic 
infarction can cause substantial morbidity and mortality,
  8 
therefore early recognition and correct treatment of PRES 
are important. 
 
Case details 
A  66-year-old  woman  was  admitted  after  a  series  of 
seizures. She reported a seizure-like episode at home, and 
then  suffered  a  generalised  tonic-clonic  seizure  in  the 
accident and emergency department which was terminated 
by intravenous lorazepam. She had a prolonged post-ictal 
phase of six hours during which her Glasgow Coma Scale 
(GCS) fluctuated between 5 to 9 (eyes score 2, verbal score 
2, motor score 5). Her daughter reported that the patient 
complained of a moderate intensity occipital headache for 
two  days  prior  to  the  first  seizure,  and  also  reported 
reduced  vision  for  approximately  six  hours  prior  to  the 
onset of seizures. She neither had a known seizure disorder 
nor  had  a  seizure  prior  to  this  admission.  Non-Hodgkin’s 
lymphoma (diffuse large B cell lymphoma) was diagnosed 
following a cervical biopsy and bone marrow examination 
two months prior.  The patient did not have any other past 
medical history of significance, and had received her first 
dose  of  chemotherapy  10  days  prior  to  the  onset  of  the 
seizures.  The chemotherapy consisted of R-CHOP. 
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There were no signs of meningeal irritation on admission; 
however  detailed  clinical  examination  was  limited  by  the 
effects  of  the  lorazepam.  Examination  of  the  chest, 
abdomen  and  cardiovascular  system  did  not  reveal  any 
abnormality.  Blood  pressure  (BP)  was  197/114  mmHg.  A 
cranial CT was reported as normal (Figure 1). Blood results 
for electrolytes (sodium, potassium, calcium, phosphate and 
magnesium), renal and liver functions were all normal, and 
C-reactive protein was 7mg/L (range 0-10mg/L). Full blood 
count  revealed  normal  platelet  count  but  severe 
neutropenia 0.2x10*9/L. Cephalosporin and acyclovir were 
commenced  empirically  in  the  emergency  department  on 
discovering neutropenia. 
 
 
Figure  1:  CT  scan  of  brain  on  admission.  Normal 
appearance of occipital lobe 
 
After  approximately  six  hours  her  GCS  improved  to  13 
(spontaneous  eye  opening,  normal  motor  function  and 
confused words) and the patient reported blurred vision. No 
signs of meningeal irritation could be elicited but detailed 
examination  was  again  limited  due  to  her  confusion. 
Lumbar puncture was planned to be performed. However, 
before  lumbar  puncture  could  be  performed,  status 
epilepticus ensued and the patient was transferred to the 
intensive care unit, received a loading dose of phenytoin, 
and  was  then  intubated  and  ventilated.  Fundoscopy 
revealed  papilledema  and  a  subsequent  cranial  CT  scan 
(second  CT  scan)  showed  oedema  in  the  occipital  lobe 
consistent with a diagnosis of PRES (Figure 2). Post diagnosis 
cephalosporin and acyclovir were immediately discontinued 
and phenytoin 100mg three times a day was continued.  Her 
neutrophil  count  increased  to  above  1x  10*9/L  over  the 
following three days and she was weaned off ventilation in 
48 hours. She had three more seizures while being removed 
from the ventilator, all of which responded to lorazepam. 
Her phenytoin was discontinued once her GCS improved to 
15 and she remained seizure free for more than 48 hours on 
day four of ITU admission. She received physiotherapy and 
made  a  complete  recovery  in  two  weeks  without  any 
residual neurological deficit.  
 
 
Figure  2:CT  scan  following  status  epilepticus.  Note  the 
oedema in occipital lobe 
 
It was difficult to be sure about the chemotherapeutic agent 
which led to development of PRES. Rituximab is a relatively 
newer  agent  in  this  regimen  of  R-CHOP.  None  of  the 
patients had developed PRES in our experience locally who 
received  CHOP  only.  A  literature  search  also  suggested 
rituximab a more likely agent than any other agent of this 
chemotherapy  regimen.  These  facts  were  discussed  with 
the patient. The patient agreed to receive her subsequent 
treatments  of  chemotherapy  without  rituximab,  and  has 
since  received  two  doses  of  CHOP  without  recurrence  of 
PRES.  It  therefore  appears  rituximab  was  linked  to  the 
observed symptoms and subsequent diagnosis of PRES. 
Discussion 
PRES is a radiological diagnosis and the condition does not 
have  pathognomonic  clinical  features.  The  diagnosis  can 
only  be  confirmed  following  a  CT  or  magnetic  resonance 
(MR)  scan  of  the  brain  with  typical  findings  of  PRES. 
Headache,  visual  problems  and  seizures  in  a  post-
chemotherapy patient with malignant disease has a broad 
differential  diagnosis  such  as  subarachnoid  haemorrhage, 
primary or secondary malignant deposits in brain, bacterial, 
viral  or  fungal  infections,  stroke,  side  effects  of 
chemotherapeutic agents and PRES. Intervention for PRES is 
minimal,  requiring  only  repeated  brain  imaging  and 
symptomatic treatment with complete recovery in most of 
cases within two weeks of onset of symptoms.
2 
 
Rituximab (anti CD 20 monoclonal antibody) is used in the 
treatment  of  patients  with  non-Hodgkin’s  lymphoma  in 
addition to its use in conditions such as lupus-related renal  Australasian Medical Journal [AMJ 2011, 4, 9, 513-515] 
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failure
9  and  sarcoidosis.  There  have  been  a  handful  of 
reports  detailing  cases  of  patients  developing  PRES  after 
receiving rituximab.
9,10 Patients in these reports developed 
symptoms  early,  even  within  a  few  hours  of  receiving 
rituximab,  and  symptoms  lasted  for  a  day  or  two  before 
disappearing without leaving any neurological deficit.  
 
This  patient’s  course  of  disease  was  similar  to  these 
previously  reported  cases;  however  symptom  onset  was 
much more delayed. The onset of symptoms 10 days after 
receiving  chemotherapy  makes  intracranial  haemorrhage 
due to thrombocytopenia, infection due to neutropenia, or 
metabolic  disorder  due  to  tumour  lyses  syndrome  also 
possible diagnoses in this patient in addition to PRES except, 
the onset of symptoms was delayed.  
 
High  BP  is  mostly  a  non-specific  finding  in  most  acute 
medical admissions, and this patient did have very high BP 
on admission. Most of the patients reported to have PRES 
were associated with hypertension as well.
7 This is one of 
the  possible  explanations  for  development  of  PRES, 
however it is difficult to be certain if very high BP leads to 
PRES or PRES leads to very high BP, especially when another 
case  report  of  PRES  did  not  have  very  high  BP.
8 
Immunosuppression has also been found to be associated 
with  PRES  in  a  few  case  reports  (e.g.  gemcitabine, 
cisplatin).
11-13  This  patient  developed  symptoms  of  PRES 
once  her  neutrophil  count  dropped  very  low,  possibly 
because  of  a  combination  of  immunosuppression  and 
hypertension which leads to development of PRES.
 
 
This case study describes a late presentation of PRES after a 
first  dose  of  rituximab,  a  combination  which  has  not 
previously been reported. PRES should not be considered a 
first-line  diagnosis  in  every  immunocompromised  patient 
who presents to the emergency department with seizures 
and high BP as the condition is rare and there are no specific 
clinical signs. However, it is worth considering if a definitive 
diagnosis  cannot  be  reached  in  a  patient  with  similar 
presentation  or  if  a  patient  does  not  show  improvement 
with initial treatment. On the basis of this case PRES should 
be considered in patients who present late even after their 
first dose of rituximab.  
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